In 2023, there will be significant interest in glial cell models, neuroinflammatory biomarkers, and optimizing approaches to target LRKK2, TREM2, and other neurological indications. As a result, large biopharmaceutical companies are expanding their departments in these areas. The 5th Annual Neuroimmunology Drug Development meeting will bring together over 100 experts in neuroinflammation and neuroimmunology from various neurological indications, including AD, PD, ALS, and MS. Participants will include discovery, preclinical, translational, and clinical experts from Genentech, Muna Therapeutics, Biogen, Janssen, Bristol Myers Squibb, Sanofi, Takeda, and Roche.
This event will feature new speakers from leading biopharmaceutical companies who will deliver pioneering and cutting-edge content. Attendees will have the opportunity to explore strategy, creation, and implementation of research, biomarker, and clinical hypothesis testing in neuroimmunology. The speaker faculty will include Bastian Zinnhardt, Biomarker Experimental Medicine Leader at Roche; Fabrizio Gasparini, Executive Director at Novartis AG; Kevin Dines, Senior Director - Scientific, Preclinical Sciences & Neuroscience at Bristol Myers Squibb; Manuela Polydoro, Head of Translational Medicine at Muna Therapeutics; Matija Zelic, Senior Scientist at Sanofi; and Sherman Jia, Group Director - Medical & Biomarker Development at Genentech Inc. Don't miss this crucial chance to join this niche audience of innovators with a shared desire to advance the field of neuroimmunology.